Valor Estate Limited Board Approves Q3 Unaudited Financial Results and Director Changes
The Board of Valor Estate Limited (formerly DB Realty) approved the unaudited standalone and consolidated financial results for the quarter…
JM Financial Limited Q3 FY26 Earnings Call Transcript Highlights Strong Profit Growth and Strategic Expansion
JM Financial reported a robust Q3 FY26, with consolidated Profit After Tax (PAT) surging 50% YoY to INR313 crores. Operating PAT (adjusted)…
Neogen Chemicals Ltd. Board Approves Q3 Financial Results and In-Principle Approval for ₹150 Crore Preferential Equity Issue
Neogen Chemicals Limited announced the outcome of its Board meeting held on February 11, 2026. The Board approved the Un-audited Standalone…
NEOGEN Chemicals Ltd. Board Approves Q3 FY26 Financial Results and ₹150 Cr Preferential Issue
NEOGEN Chemicals Limited’s Board approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2025. Key…
Bandhan Bank RBI Approves 9.95% Stake Acquisition by ICICI Prudential AMC Group
The Reserve Bank of India (RBI) has approved the acquisition of up to 9.95% of Bandhan Bank’s paid-up share capital or voting rights.…
Power Mech Projects Limited Strong Q3 FY2026 Results Show 6% Revenue Growth and Expanding Order Book
Power Mech Projects Limited announced its Un-audited Financial Results for the quarter and nine months ending December 31, 2025 (Q3 FY2026).…
Neogen Chemicals Ltd. Board Approves Q3 Unaudited Results and ₹150 Crore Preferential Share Issue
Neogen Chemicals Ltd. announced the outcome of its Board meeting held on February 11, 2026. The Board approved the Un-audited Standalone and…
Eureka Forbes Limited Transcript of Q3 FY26 Earnings Conference Call Held on February 5, 2026
Eureka Forbes reported a resilient Q3 FY26 performance with 8% YoY revenue growth and an adjusted EBITDA margin expansion of 57 basis points…
Choice International Limited Disclosure of Earnings Call Transcript for Q3 FY26 Results
Choice International Limited has made the transcript of its Q3 FY26 earnings conference call publicly available. The call discussed the…
Orchid Pharma Limited Submission of Monitoring Agency Report for Q3 FY2025-26
Orchid Pharma Limited has submitted the Monitoring Agency Report for the Quarter-III ended December 31, 2025, regarding the utilization of…